Daiichi Sankyo, the Japanese owner of Ranbaxy Laboratories, has deputed two executives to monitor the Indian drug maker's new plant that will be the main source for supplying medicines for the US market. A person aware of the development said these two executives, who are at the general manager and director level, would be based at the company's new facility at Mohali, Punjab, which was approved by the US Food and Drug Administration (FDA) last month.
